MynoSys Cellular Devices is an ophthalmic technology company structured around providing surgeons with innovative solutions that enable procedural excellence particularly inthe cataract surgery space. With continuing NIH SBIR support over several years, the firm has developed the Zepto® Precision Cataract Surgery platform - a affordable capsulotomy technology that can be a part of everyone's surgical armamentarium. Recent investment funding is targeted towards increasing global access to this device, particularly in practices where a less expensive method of automating the capsulotomy is desirable. Zepto Precision Cataract Surgery provides consistent, high quality anterior lens capsulotomies during cataract surgery in a convenient, cost-effective, disposable format. One of the key features is a collapsible super-elastic nitinol capsulotomy ring element with micron scale elements to create the unique and strong Zepto capsulotomy edge. It also has a clear silicone suction cup to enable suction and generate Zeptoâs proprietary capsulotomy action and to allow Zepto capsulotomies on the patientâs individual visual axis. Zepto integrates seamlessly into the routine steps of cataract surgery with phacoemulsification. The surgeon does not need to alter their normal routine. Instead of capsulorrhexis forceps or a cystitome, the surgeon simply reaches for Ze
